Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov;43 Suppl 2(Suppl 2):S78-S83.
doi: 10.1016/j.htct.2021.09.011.

Associação Brasileira de Hematologia, Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. Review article: Cell therapy in solid tumors

Mirella Nardo  1 , Tatiane C Motta  2 , Leandro M Colli  2 , Mauro P Avanzi  3
Affiliations
Review

Associação Brasileira de Hematologia, Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. Review article: Cell therapy in solid tumors

Mirella Nardo et al. Hematol Transfus Cell Ther. 2021 Nov.

Abstract

The use of immunotherapy in cancer treatment over the past decade has resulted in significant advances and improvements in cancer patients survival with the use of checkpoint inhibitors. Nevertheless, only a fraction of solid tumors responds to this immunotherapy modality. Another modality of immunotherapy consists of employing cell-based therapy as an adoptive therapeutic modality. That involves distinct modalities of cellular therapies such as CAR T cells (chimeric antigen receptor T cell), TILs (tumor-infiltrating lymphocytes), and TCR T cells. Those treatments have proven effective in hematologic tumors and could have an impact in tumors that do not respond to checkpoint inhibitors. This review aims to outline the rationale, operation, clinical applicability, and results of adoptive cell therapy for patients with solid tumors.

Keywords: Adoptive cell therapy; CAR-T cells; Cell therapy; Checkpoint inhibitors; Immunotherapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest Mauro P. Avanzi is an employee of Neogene Therapeutics. The other authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Basic principles of adoptive cell therapy, IL-2.interleukin-2, TIL (tumor-infiltrating lymphocytes), CAR (chimeric antigen receptors), TCR (T-cell receptor), APC (antigen-presenting cell), PBL (peripheral blood lymphocytes), antibody.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Van den Bulk J, Verdegaal EM, De Miranda NF. Cancer immunotherapy: broadening the scope of targetable tumours. Open Biol. 2018;8(6):1–10. doi: 10.1098/rsob.180037. - DOI - PMC - PubMed
    1. Velcheti V, Schalper PK. Overview. Basic overview of current immunotherapy approaches in cancer. Am Soc Clin Oncol Educ B. 2016;35:298–308. doi: 10.1016/j.urolonc.2005.08.013. - DOI - PubMed
    1. Zhang H, Ye ZL, Yuan ZG, Luo ZQ, Jin HJ, Qian QJ. New strategies for the treatment of solid tumors with CAR-T cells. Int J Biol Sci. 2016;12(6):718–729. doi: 10.7150/ijbs.14405. - DOI - PMC - PubMed
    1. Sadelain M, Rivière I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003;3(1):35–45. doi: 10.1038/nrc971. - DOI - PubMed
    1. Rooks M.G, Garrett W.S. Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know. Physiol Behav. 2017;176(3):139–148. doi: 10.1038/nrclinonc.2011.116.Cell. - DOI - PubMed